Navigation Links
GlaxoSmithKline and Genmab Present Positive Phase II Results With,ofatumumab in Patients With Rheumatoid Arthritis (RA)

people to do more, feel better and live longer. For more information, visit GlaxoSmithKline on the World Wide Web at www.gsk.com.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody(TM), a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statement
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
2. New Data on Genmab and GlaxoSmithKlines Ofatumumab: Phase II Study in Rheumatoid Arthritis to be Presented at EULAR
3. Genmabs HuMax-EGFr Shows Broad Potential in Cancer Treatment
4. The Past, Present and Future of HLA Typing
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
9. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
10. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
11. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:5/12/2008)...udy opens way for high-power permanent version of ...w study, BOSTON, May 12 /- Innovativ...on and the daily lives of patients with,hemianopia... both eyes. The,peripheral prism glasses, which we... Schepens Eye Research Institute, were evaluated i...
(Date:5/12/2008)...May 12 /- GeoVax Labs, Inc..../AIDS vaccine development,company, announced today...ck purchase agreement with Fusion Capital Fund II,...e Company may sell up to $10 million of its common...25-month period after the Securities and,Exchange ...
(Date:5/12/2008)..., Mich., May 12 /- Velcura Therapeuti...first-in-man clinical trial for,its lead compound,...,treatment for Rheumatoid Arthritis (RA) and other...VEL-0230 proved to be a powerful,anti-inflammatory...ibits,bone loss. Taken together, these characteris...
(Date:5/12/2008)...the Optimal Combination of Scaffolding, Deliverabi...y, TEL AVIV, Israel, May 12 /- Medin...rk for its Presillion(TM) CoCr Coronary Stent,ena...with a technologically,innovative flexible closed ...superb scaffolding the unprecedented,balance of fl...
Breaking Medicine Technology:Prism Glasses Expand the View for Patients with Hemianopia 2Prism Glasses Expand the View for Patients with Hemianopia 3GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy 2Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 1The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 2The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 3The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 4The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase like Protein YKL 40 in Patients With Asthma 850 5JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 1JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 2JDRF and Lilly partner to fund research to identify beta cell biomarkers 6355 3Yale discovery suggests protein may play a role in severe asthma 1224 1Yale discovery suggests protein may play a role in severe asthma 1224 2Carrington Reports on ISO 9001 3A2000 Inspection 1807 1Carrington Reports on ISO 9001 3A2000 Inspection 1807 2
...ata Presented at 2007 APA Meeting -, COLLEGEVILLE,...from four new studies examining safety and efficac...ephrine reuptake,inhibitor (SNRI) being studied as...ssive disorder (MDD), were presented today at the,...ng in San Diego,Calif., by Wyeth Pharmaceuticals,...
...ion Antibody Led to a Sustained Response and Remis... and Was Adequately,Tolerated in Patients with IV ...lif., May 22, 2007 /PRNewswire-FirstCall/ -- Data,...ing this week in,Washington D.C. by Dr. William Sa...isilizumab), an antibody in development as a,treat...
Other Medicine Technology:New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 2New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 3New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 4New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 5New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 6New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 7New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder 8PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 2PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 3PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 4PDL BioPharma Announces Long-Term Nuvion Data Presented at 2007,Digestive Disease Week 5
(Date:5/12/2008)...swire-FirstCall/ -- Nationwide,Health Properties, ...r joined,NHP today as its Vice President and Contr...ice President and Chief Accounting Officer for Sun...o had experience in Finance and,Accounting with se... as,over seven years of experience with a "Big 4" ...
(Date:5/12/2008)...l/ - Med-Emerg International Inc.,(OTCBB - MDER), ...tions,for the three months ended March 31, 2008 w...same period in 2007 (all amounts are $US unless,ot...ngs before,depreciation, amortization, interest an...($106K) in 2007. The improvement in EBITDA arose l...
(Date:5/12/2008)...swire/ -- Baptist Health South,Florida Inc., a hea... to,pay the United States $7,775,000 to settle cla...Stark Statute between 2003 and 2005, by paying,exc...a source of patient,referrals to two of Baptist,s ...ay. The payments were made pursuant to a contract ...
(Date:5/12/2008)...all/ -- Allied Healthcare Products,Inc. (Nasdaq: ... third,quarter ending March 31 fell 64 percent, fr... to about $100,000 in the current quarter, or 1 ce...sed by about $240,000 compared to the,third quarte...labor costs,this fiscal year eroded margins and pr...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:Florida Hospital Group Pays U.S. $7,775,000 to Settle False Claims Act Allegations 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5
...mass index (BMI) tend are less likely to be discha...chemic stroke// , according to a report. An ische... of the brain is blocked or reduced and sufficient... to brain tissue. Obesity and excess weight are ri...
...evealed that autism is far more complex than had b... National Institute for Mental Health// , seems to...ny as 100 different genes. It turns out many dif...ally result in autism and this certainly complicat...
... has welcomed a decision by Pharmac(the Pharmaceut...gs//. At the same time, they say delays over the f...o new medicines, to be subsidized from April 1, 20...mtricitabine (Emtriva), Pharmac announced. Accor...
...count test done using Transvaginal sonography is a...xpensive and time consuming hormone tests. As the...rent ovarian reserve tests, clinicians may in futu...d scans of a woman's ovaries to predict her ovarie...
Other Medicine News:Health News:Stroke Patients With High BMI Less Likely to Be Discharged After Hospitalization 2Health News:New Zealand’s Pharmac Subsidies Two More HIV Drug 2
Tibial distractor
...rsaPulse® PowerSuite™ holmium laser comb...roperties for precise, virtually bloodless procedu... urinary and gall bladder stones of all compositio... Because its laser light is transmitted through fl...
...rsaPulse® PowerSuite™ holmium laser comb...roperties for precise, virtually bloodless procedu... urinary and gall bladder stones of all compositio... Because its laser light is transmitted through fl...
... Mayo Knee Positioner reduces surgeon fatigue and ...ring surgery. The positioner's single locking lev..., tilt, and rotation. The same lever releases the...ge of motion testing. The positioner is easily se...
Medicine Products: